Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Rhythm Pharmaceuticals (NASDAQ:RYTM) in the last three months.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
3
1
0
0
0
Last 30D
1
0
0
0
0
1M Ago
1
1
0
0
0
2M Ago
0
0
0
0
0
3M Ago
1
0
0
0
0
In the assessment of 12-month price targets, analysts unveil insights for Rhythm Pharmaceuticals, presenting an average target of $50.5, a high estimate of $52.00, and a low estimate of $50.00. Highlighting a 4.72% decrease, the current average has fallen from the previous average price target of $53.00.
Understanding Analyst Ratings: A Comprehensive Breakdown
The perception of Rhythm Pharmaceuticals by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst
Analyst Firm
Action Taken
Rating
Current Price Target
Prior Price Target
Joseph Stringer
Needham
Maintains
Buy
$50.00
-
Derek Archila
Wells Fargo
Lowers
Overweight
$52.00
$53.00
Joseph Stringer
Needham
Maintains
Buy
$50.00
-
Joseph Stringer
Needham
Maintains
Buy
$50.00
-
Key Insights:
Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Rhythm Pharmaceuticals. This information provides a snapshot of how analysts ...Full story available on Benzinga.com
Benzinga
